Avadel Pharmaceuticals plc (AVDL)
Automate Your Wheel Strategy on AVDL
With Tiblio's Option Bot, you can configure your own wheel strategy including AVDL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AVDL
- Rev/Share 2.0129
- Book/Share 0.7668
- PB 12.3898
- Debt/Equity 0.0391
- CurrentRatio 2.7341
- ROIC -0.1629
- MktCap 919019503.0
- FreeCF/Share -0.2633
- PFCF -36.1321
- PE -34.7486
- Debt/Assets 0.0172
- DivYield 0
- ROE -0.3607
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AVDL | Deutsche Bank | -- | Buy | -- | $12 | Feb. 11, 2025 |
News
Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may be clinically superior to the same drug(s) already approved for the same indication, because LUMRYZ may provide a major contribution to patient care due to its once-nightly dosing for patients with IH, a chronic sleep disorder that requires potentially lifelong …
Read More
Wall Street Analysts Think Avadel (AVDL) Could Surge 97.68%: Read This Before Placing a Bet
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 97.7% in Avadel (AVDL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
All You Need to Know About Avadel (AVDL) Rating Upgrade to Buy
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Avadel (AVDL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter the idiopathic hypersomnia market after a favorable court ruling. Analysts remain bullish, reiterating Buy ratings and projecting significant revenue and profit growth through FY2026 as LUMRYZ adoption accelerates.
Read More
Earnings Estimates Moving Higher for Avadel (AVDL): Time to Buy?
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Wall Street Analysts Believe Avadel (AVDL) Could Rally 100.21%: Here's is How to Trade
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Avadel (AVDL) points to a 100.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call Transcript
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Austin Murtagh - IR Greg Divis - CEO Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies David Amsellem - Piper Sandler Mark Goodman - Leerink David Huang - Deutsche Bank Myriam Belghiti - LSC Ami Fadia - Needham Chase Knickerbocker - Craig Hallum Operator Greetings, and welcome to Avadel Pharmaceuticals First Quarter 2025 Earnings Call. At this time, all participants are in a listen only mode.
Read More
Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
-- Generated $52.5 million in net revenue from sales of LUMRYZ™, a 93% increase over the first quarter of 2024 -- -- 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 --
Read More
Avadel Pharmaceuticals Announces Favorable Ruling in Appeal of Delaware Court Injunction
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
- With this ruling, Avadel can seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia - - Federal Circuit decision permits new clinical trials and further development of LUMRYZ™ for the treatment of indications beyond narcolepsy - DUBLIN, Ireland, May 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) has ruled in favor of Avadel, overturning important parts of the injunction imposed by the U.S. District Court for the District of …
Read More
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2025 Financial Results on May 7
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, Ireland, April 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, May 7, 2025, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2025.
Read More
Avadel Pharmaceuticals Provides Update at Needham Virtual Healthcare Conference
Published: April 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today presented at the 24th Annual Needham Virtual Healthcare Conference.
Read More
Avadel Announces Publications in CNS Drugs Supplement Highlighting Key Clinical Issues for People with Narcolepsy and Their Clinicians
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, March 25, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of six manuscripts covering clinical management, shared decision-making and goal setting for people with narcolepsy and their clinicians in a CNS Drugs supplement titled “A New Dawn in the Management of Narcolepsy”.
Read More
Avadel Pharmaceuticals Appoints Kevin Springman as Vice President of Sales
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that Kevin Springman has joined the company as Vice President of Sales. Mr. Springman is an accomplished executive with experience leading sales, market access and commercial teams, and executing rare disease drug launches in competitive markets.
Read More
About Avadel Pharmaceuticals plc (AVDL)
- IPO Date 1996-06-07
- Website https://www.avadel.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Gregory J. Divis Jr.
- Employees 188